Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

• Post published:October 1, 2022
• Post category:Press Release

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

• Post published:September 28, 2022
• Post category:Press Release

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

• Post published:September 15, 2022
• Post category:Press Release

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

• Post published:July 28, 2022
• Post category:Press Release

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

• Post published:July 15, 2022
• Post category:Press Release

Silo Pharma Expands License Agreement and Patent Portfolio

• Post published:June 23, 2022
• Post category:Press Release

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

• Post published:March 31, 2022
• Post category:Press Release

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

• Post published:February 3, 2022
• Post category:Press Release

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

• Post published:December 14, 2021
• Post category:Press Release

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

• Post published:December 2, 2021
• Post category:Press Release